Technical Analysis for VYGR - Voyager Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 10.9 2.83% 0.30
VYGR closed up 2.83 percent on Friday, February 28, 2020, on 1.37 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 3
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical VYGR trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.83%
New 52 Week Low Weakness 2.83%
Wide Bands Range Expansion 2.83%
Lower Bollinger Band Touch Weakness 2.83%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease; and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's ataxia, and VY-HTT01 for Huntington's disease, as well as VY-SMN101 for neuromuscular disease. The company has strategic collaborations with Genzyme Corporation and the University of Massachusetts Medical School. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Medicine Health Manufacturing Gene Therapy Genetics Parkinson's Disease Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Huntington's Disease Sanofi Friedreich's Ataxia Severe Diseases

Is VYGR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.76
52 Week Low 10.13
Average Volume 311,198
200-Day Moving Average 17.80
50-Day Moving Average 13.05
20-Day Moving Average 12.39
10-Day Moving Average 12.06
Average True Range 0.77
ADX 20.56
+DI 12.92
-DI 33.32
Chandelier Exit (Long, 3 ATRs ) 11.65
Chandelier Exit (Short, 3 ATRs ) 12.43
Upper Bollinger Band 14.29
Lower Bollinger Band 10.50
Percent B (%b) 0.11
BandWidth 30.54
MACD Line -0.48
MACD Signal Line -0.27
MACD Histogram -0.2109
Fundamentals Value
Market Cap 293.24 Million
Num Shares 26.9 Million
EPS -2.31
Price-to-Earnings (P/E) Ratio -4.72
Price-to-Sales 69.72
Price-to-Book 5.32
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.16
Resistance 3 (R3) 12.04 11.51 11.95
Resistance 2 (R2) 11.51 11.19 11.57 11.88
Resistance 1 (R1) 11.20 10.99 11.36 11.32 11.81
Pivot Point 10.67 10.67 10.74 10.73 10.67
Support 1 (S1) 10.36 10.35 10.52 10.48 9.99
Support 2 (S2) 9.83 10.15 9.89 9.92
Support 3 (S3) 9.52 9.83 9.85
Support 4 (S4) 9.64